Wednesday, 17 Oct 2018

You are here

The RheumNow Week in Review – Good News for GPA, CZP, Tofa but not ERA (6.1.18)

Dr. Jack Cush reviews this weeks reports from RheumNow.com, including the risk of autoimmunity with vaccination, early RA outcomes, new FDA approvals for certolizumab and tofacitinib and the risk of death from infection with biologics.

  1. UCB announces the FDA has approved Cimzia (certolizumab) for use in moderate to severe plaque psoriasis based on over 1000 pts in Phase 3 RCTs CIMPASI-1, CIMPASI-2 and CIMPACT and PASI75 of 75-82% at wk16. Certolizumab is now FDA approved for use in Crohns disease, Rheumatoid arthritis, Ankylosing spondylitis, psoriatic arthritis and now Psoriasis. https://t.co/PYx15htd3Z
  2. Pfizer announces that the FDA has approved Xeljanz (tofacitinib) 10 mg twice-daily (BID) for at least 8 Wks, followed by 5 mg BID or 10 mg BID, for adults with active ulcerative colitis (UC). This is 1st approval of 10mg bid dose https://t.co/z5hb5p8psF
  3. In RCTs, among 1157 ulcerative colitis pts receiving tofacitinib, 65 (5.6%) developed herpes zoster, 11 multidermatomal & 1 HZ encephalitis. HZ=4.07 with higher risk in elderly, Asians, prior TNFi failure & tofa 10 mg bid. http://bit.ly/2kEOjzH
  4. CMAJ reports on a Canadian population study of 290,939 girls 12–17 yrs who received quadravalent HPV vaccine with no increased risk of subsequent autoimmune disease (eg, Graves, Bells, JIA, SLE, AIHA, etc) https://t.co/jtJBDlE6jv
  5. US Renal Transplant system review ~20 yr data shows Renal transplantation results in a significant decrease (70%) in mortality among ESRD GPA patients, largely due to a 90% decrease in CVD death. https://t.co/vdWwGxJMvO 
  6. ESPOIR 5 Yr study of 403 early RA patients shows radiographic progression occurred in 143 (35.5%), more likely with high dose steroids and less likely with >36 mos of biologic therapy. https://t.co/onKuurpwZL 
  7. In a DMARD naive, early RA cohort (U-Act) study, 52% were MTX-IR at 1 year;  predictors of inadequate response to MTX included higher DAS28 (OR=2), current smoking (OR=3) and no alcohol consumption. https://t.co/FTxv5ZxObP
  8. British Biologics Registry of 19282 RA patients -the biologic SIE rate was 5.51 per 100 patient-yrs. The risk of death in the first 30days following a serious infection was 10% https://t.co/sIwd9S8QJM
  9. Increased Risk of Depression and Anxiety in Rheumatoid Arthritis  
  10. Cancer Risk Raised in Psoriatic Arthritis  

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Week in Review – Four Fingers are Best (10.12.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. New info on scleroderma-SLE overlap, nailfold capillaroscopy, Women with SpA, acute gout management and lupus patient in pain who visit the ED.

RheumNow Week in Review – Vitamin D Falls Again (10.4.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com. 

RheumNow Week in Review – I Wanna New Drug (9.28.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.

CDC: 2017 Record Number of Influenza Deaths

The CDC reports that in 2017, influenza killed and hospitalized more people in the United States than any other year in the last few decades. (Citation Source http://bit.ly/2DBr0TE)

RheumNow Week in Review – RheumNow Live Meeting Announcement (9.21.18)

Dr. Jack Cush reviews the news and updates from the past week on RheumNow.